NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Forecast & News

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Reata Pharmaceuticals Inc (NASDAQ:RETA) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.25) by $0.07. The business earned $8.24 million during the quarter, compared to analyst estimates of $7.43 million. Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,281.61%. The firm's revenue for the quarter was up 59.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.07) earnings per share. View Reata Pharmaceuticals' Earnings History.

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Reata Pharmaceuticals.

8 brokerages have issued twelve-month target prices for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $328.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $255.63 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

Media headlines about RETA stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Reata Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Reata Pharmaceuticals.

Some companies that are related to Reata Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF) and Catalent (CTLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), First Financial Bankshares (FFIN), Precision Drilling (PDS), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Precision Drilling (PD) and Gilead Sciences (GILD).

(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Reata Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.23%), Columbus Circle Investors (0.18%), Assenagon Asset Management S.A. (0.12%), Woodstock Corp (0.05%), Penn Davis Mcfarland Inc. (0.02%) and Tocqueville Asset Management L.P. (0.01%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Institutional Ownership Trends for Reata Pharmaceuticals.

RETA stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp, Tocqueville Asset Management L.P., Dupont Capital Management Corp and Nisa Investment Advisors LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

RETA stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Assenagon Asset Management S.A., California Public Employees Retirement System, Penn Davis Mcfarland Inc., Zeke Capital Advisors LLC, Strs Ohio, Optimum Investment Advisors and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass and James W Traweek Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RETA stock can currently be purchased for approximately $196.27.

Reata Pharmaceuticals has a market capitalization of $5.94 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.

The official website for Reata Pharmaceuticals is http://www.reatapharma.com/.

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]